Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral m…

Biotechnology

US, Menlo Park [HQ]

Analysts
Dividend Payments
Government Awards
Insiders
Lobbying Expenses
Segment Revenues
Shareholder Structure
Supply / Portfolio
Valuation Models [Soon]

Financials

Analysts

Wall Street · Earnings · Institutional Sentiment

A comprehensive analysis section that covers unveiling insights about Corcept Therapeutics Incorporated's gradings, price targets and earnings estimates. None

Earnings
Grading & Price

Reported

Past Estimate Consensus

Future Estimate Consensus

EPS Revenue EBITDA EBIT SGA

All monetary values are presented in USD ($). E stands for Estimate.

Download

FY	EPS		Revenue [mil.]		Profit [mil.]		EBITDA [mil.]		EBIT [mil.]		Expenses · SGA [mil.]
		E		E		E		E		E		E
2015	-0.3100	-0.100	26	50	-31	-11	-27	15	-27	15	34	17
2016	-0.0600	0.040	50	80	-6	4	-3	25	-3	24	36	27
2017	0.0700	0.428	81	159	8	131	10	50	10	50	45	56
2018	1.1400	0.570	159	251	129	81	52	99	52	96	62	88
2019	0.6000	0.803	251	306	75	97	89	122	89	115	81	105
2020	0.8200	0.840	306	358	94	103	111	130	111	124	100	104
2021	0.9200	0.893	353	367	106	90	128	99	128	96	105	99
2022	0.9700	0.955	365	403	112	107	124	130	124	125	122	135
2023	0.9500	0.922	401	476	101	105	112	143	112	137	152	148
2024	1.0200	1.360	482	691	106	151	109	217	107	213	184	238
2025	-	1.912	-	810	-	224	-	255	-	250	-	279
2026	-	2.F11X/td>	-	2.F11X/td>	-	2.F11X/td>	-	2.F111/td>	-	2.F111	-	2.F111
2027	-	1.F12X/td>	-	1.F12X/td>	-	1.F12X/td>	-	1.F121/td>	-	1.F121	-	1.F121
2028	-	0.F13X/td>	-	0.F13X/td>	-	0.F13X/td>	-	0.F131/td>	-	0.F131	-	0.F131